They consider a number of criteria, including effectiveness and cost. They also consider that, in a number of cases, changing one molecule in a new drug is not going to improve the patient's quality of life. In those cases, they stick with the drug that they already have. The so-called cross deals affect the cost of drugs too. It's quite interesting. We can talk about access to medicines, but the impact of their cost on the entire health care system is an issue too. When we talk about the health care portfolio, we know that a large part of the funding goes to pharmacare and hospitals. They have decided to put less pressure on the entire health care area.
On April 16th, 2007. See this statement in context.